Last Updated: June 23, 2026

BROMOCRIPTINE Drug Patent Profile

Name: BROMOCRIPTINE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Bromocriptine, and when can generic versions of Bromocriptine launch?

Bromocriptine is a drug marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Aurobindo Pharma Usa, Padagis Us, and Sandoz. and is included in six NDAs.

The generic ingredient in BROMOCRIPTINE is bromocriptine mesylate. There are nine drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the bromocriptine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Bromocriptine

A generic version of BROMOCRIPTINE was approved as bromocriptine mesylate by SANDOZ on January 13^th, 1998.

Start Trial

AI Deep Research

Questions you can ask:

What is the 5 year forecast for BROMOCRIPTINE?
What are the global sales for BROMOCRIPTINE?
What is Average Wholesale Price for BROMOCRIPTINE?

Summary for BROMOCRIPTINE

US Patents:	0
Applicants:	6
NDAs:	6
Drug Prices:	Drug price information for BROMOCRIPTINE
DailyMed Link:	BROMOCRIPTINE at DailyMed

Drug patent expirations by year for BROMOCRIPTINE

US Patents and Regulatory Information for BROMOCRIPTINE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lek Pharm	BROMOCRIPTINE MESYLATE	bromocriptine mesylate	CAPSULE;ORAL	075100-001	Dec 10, 1998		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Aurobindo Pharma Usa	BROMOCRIPTINE MESYLATE	bromocriptine mesylate	TABLET;ORAL	076962-001	Sep 24, 2004		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Mylan	BROMOCRIPTINE MESYLATE	bromocriptine mesylate	CAPSULE;ORAL	077226-001	Apr 4, 2005	AB	RX	No	Yes	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.